Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Cash from Financing Activities
Exelixis Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exelixis Inc
NASDAQ:EXEL
|
Cash from Financing Activities
-$546.1m
|
CAGR 3-Years
-179%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-47%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Exelixis Inc's Cash from Financing Activities?
Cash from Financing Activities
-546.1m
USD
Based on the financial report for Dec 29, 2023, Exelixis Inc's Cash from Financing Activities amounts to -546.1m USD.
What is Exelixis Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-47%
The average annual Cash from Financing Activities growth rates for Exelixis Inc have been -179% over the past three years , and -47% over the past ten years .